SCHEMBL6319339

SCHEMBL6319339

Cc1c(-c2cc3ccccc3o2)c(Cl)n2c(nc3ccccc32)c1C#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
NPSR1 Q6W5P4 4/20 0.57
LMNA P02545 4/20 0.57
RAB9A P51151 2/20 0.57
NPC1 O15118 1/20 0.57
MDM2 Q00987 1/20 0.57
HSP90AA1 P07900 1/20 0.56
KMT2A Q03164 6/20 0.54
HPGD P15428 3/20 0.54
HTT P42858 2/20 0.54
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 7/20 0.53
GAA P10253 4/20 0.53
POLB P06746 4/20 0.53
GLA P06280 1/20 0.53
XBP1 P17861 1/20 0.53
MEN1 O00255 4/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6311460 0.82 KMT2A (0.63) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6310360 0.80 MAPT (0.67) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6319170 0.78 MAPT (0.56) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6312695 0.78 MAPT (0.60) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6316790 0.77 ALDH1A1 (0.45) NPSR1LMNAKMT2AHPGDHTT
SCHEMBL6312781 0.77 MAPT (0.73) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6311916 0.77 MAPT (0.59) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6312618 0.76 MAPT (0.58) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6311036 0.75 MAPT (0.60) MAPTSMN1; SMN2NPSR1LMNARAB9A
SCHEMBL6309843 0.75 MAPT (0.70) MAPTSMN1; SMN2NPSR1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601674-A2 HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2005-12-07 EP disclosed
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed
WO-2004022558-A2 HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 MAPT 1694/4885SMN1; SMN2 2642/4885NPSR1 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.